From the publishers of JADPRO

Multiple Myeloma Resource Center

Advertisement

Expert perspectives on current challenges and emerging approaches for multiple myeloma: Narrative review of an inaugural bridging the gaps in leukemia, lymphoma, and multiple myeloma

Last Updated: Thursday, April 10, 2025

A panel of experts discussed the increasingly complex management of multiple myeloma (MM), focusing on controversies in treatment sequencing and selection. Key topics included smoldering MM, transplant eligibility, risk assessment, MRD, relapse management, and novel therapies. Many controversies remain regarding risk assessment, treatment selection, and optimal use of therapies, necessitating further research for improved and more efficacious treatments.

Clinical Lymphoma, Myeloma & Leukemia
Advertisement
News & Literature Highlights

Nature Reviews. Clinical Oncology

EHA-EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma

Discover Oncology

Deciphering and targeting oncogenic pathways through integrated approaches and amino acid metabolism in hematologic malignancies

The Journal of the American Academy of Orthopaedic Surgeons

Influence of chimeric antigen receptor T-cell therapy on fracture risk of patients with multiple myeloma

Cancer Nursing

Dynamic changes in symptom clusters and symptom networks in patients with multiple myeloma: Across-lagged network analysis

Clinical Lymphoma, Myeloma & Leukemia

Practical guidance on the clinical management of belantamab mafodotin for patients with relapsed/refractory multiple myeloma: Recommendations from the Middle East and North Africa expert panel

Future Oncology

Community hematologist/oncologist perspectives on minimal residual disease testing in patients with multiple myeloma

International Journal of Molecular Sciences

Breaking barriers: The role of the bone marrow microenvironment in multiple myeloma progression

HemaSphere

Early peripheral blood and bone marrow MRD as prognostic markers in quadruplet-treated multiple myeloma without transplant

Nature Cancer

ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells

ASCO 2025

DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone vs pomalidomide plus bortezomib and dexamethasone in relapsed/refractory multiple myeloma: A subgroup analysis in patients with high-risk cytogenetic features

Advertisement
Advertisement